Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy
Authors:
- Tadahiko YanagitaTYTadahiko Yanagita
- Yoji MurataYMYoji Murata
- Daisuke TanakaDTDaisuke Tanaka
- Sei-Ichiro MotegiSMSei-Ichiro Motegi
- Eri AraiEAEri Arai
- Edwin Widyanto DaniwijayaEDEdwin Widyanto Daniwijaya
- Daisuke HazamaDHDaisuke Hazama
- Ken WashioKWKen Washio
- Yasuyuki SaitoYSYasuyuki Saito
- Takenori KotaniTKTakenori Kotani
- Hiroshi OhnishiHOHiroshi Ohnishi
- Per-Arne OldenborgPOPer-Arne Oldenborg
- 12 January 2017
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (1) , e89140
Abstract
Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRPα is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRPα Ab that blocks the interaction with CD47 markedly suppressed tumor formation by renal cell carcinoma or melanoma cells in immunocompetent syngeneic mice. This inhibitory effect of the Ab appeared to be mediated by dual mechanisms: direct induction of Ab-dependent cellular phagocytosis of tumor cells by macrophages and blockade of CD47-SIRPα signaling that negatively regulates such phagocytosis. The antitumor effect of the Ab was greatly attenuated by selective depletion not only of macrophages but also of NK cells or CD8 + T cells. In addition, the anti-SIRPα Ab also enhances the inhibitory effects of Abs against CD20 and programmed cell death 1 (PD-1) on tumor formation in mice injected with SIRPα-nonexpressing tumor cells. Anti-SIRPα Abs thus warrant further study as a potential new therapy for a broad range of cancers.Keywords
This publication has 61 references indexed in Scilit:
- CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and DiseaseISRN Hematology, 2013
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Therapy for metastatic melanoma: the past, present, and futureBMC Medicine, 2012
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated AntigensImmunity, 2011
- Regulation by SIRPα of dendritic cell homeostasis in lymphoid tissuesBlood, 2010
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009